
Please try another search
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company’s proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Name | Age | Since | Title |
---|---|---|---|
James A. Helliwell | 51 | 2012 | CEO & Director |
Simon N. Pimstone | 57 | 2013 | Independent Chairman |
Michael Wilmink | - | 2013 | Independent Director |
John Salvatore Montalbano | 60 | 2013 | Independent Director |
Richard M. Glickman | 67 | 2021 | Independent Director |
Joseph S. Freedman | 55 | 2024 | Independent Director |
Evan S. Dellon | - | 2024 | Chairman of Clinical Advisory Board |
Paul L. Geyer | 61 | 2013 | Independent Director |
Roos Pouw | - | 2024 | Member of Clinical Advisory Board |
Nirmala Gonsalves | - | 2024 | Member of Clinical Advisory Board |
Stephen Attwood | - | 2024 | Member of Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review